We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Merck and Co Inc | NYSE:MRK | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.43 | 0.33% | 131.15 | 131.91 | 130.13 | 130.13 | 7,757,432 | 00:26:37 |
From Apr 2019 to Apr 2024
By Carlo Martuscelli
The U.S. Food & Drug Administration has granted orphan drug designation tp AstraZeneca PLC's (AZN.LN) and Merck & Co. Inc.'s (MRK) Lynparza to treat pancreatic cancer, Astra said Tuesday.
Orphan drug designation is given to medicines that aim to treat rare diseases and provides benefits such as market exclusivity and tax breaks. Lynparza was previously granted orphan drug status for ovarian cancer, as well as fallopian tube and primary peritoneal cancer.
Lynparza is being developed by AstraZeneca and Merck & Co. as part of a strategic collaboration in the field of oncology. It is currently undergoing a phase 3 trial, with results expected in the first half of 2019.
Write to Carlo Martuscelli at carlo.martuscelli@dowjones.com
(END) Dow Jones Newswires
October 16, 2018 02:36 ET (06:36 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
1 Year Merck Chart |
1 Month Merck Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
